0.00Open0.00Pre Close0 Volume0 Open Interest35.00Strike Price0.00Turnover0.00%IV-236.86%PremiumDec 20, 2024Expiry Date24.61Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.43Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Avadel Pharmaceuticals Stock Discussion
yeah, cluster buys drew my attention too
– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challen...
🎃⚡️🎃
Given its current financial standing and market movements, Avadel Pharmaceuticals is assessed as a moderately high-risk investment. The company's unprofitability, negative cash flow, and strong dependency on news-related catalysts pose potential risks. Nonetheless, the recently improved stock sentiment, coupled with analysts' positive forecasts, suggests some upside potential. The relatively high position in its volatility scale underscores the need for caution,...
📊⚡️📊
4 mins ago
Avadel Pharmaceuticals Announces FDA Approval of Lumryz™ (Sodium Oxybate) Extended-Release Oral Suspension (Ciii) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older With Narcolepsy
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...
No comment yet